Delivering Value To Those We Serve

Overview

Recent News

Date Title and Summary
Toggle Summary Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results
-- Reports Neurology Franchise Annual Net Sales of $110.3 million , at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales -- LAKE FOREST, Ill.
Toggle Summary Assertio Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results After The Close of Markets on Wednesday, March 6, 2019
LAKE FOREST, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019 , after the close of markets. Following the announcement, the Company will host a
Toggle Summary Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin
Company Anticipates Potential Market Launch by Early 2020 LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration ( FDA ) for its 505(b)(2)

Upcoming Events

There are currently no events to display.
Presentations

Recent SEC Filings

Filing date Description Form Filing Group View

Optional form for the registration of securities to be sold to the public by small business issuers

SB-2
Registration Statements
View HTML

Pre-effective amendment to an SB-2 filing

SB-2/A
Registration Statements
View HTML

Registration of certain classes of securities 12(b) of the Securities Exchange Act

8-A12B
Registration Statements
View HTML

Substantive changes from or additions to a prospectus previously filed

424A
Registration Statements
View HTML

Pre-effective amendment to an SB-2 filing

SB-2/A
Registration Statements
View HTML

IR Contact

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com
 

Independent Registered Public Accounting Firm

Ernst & Young LLP
Palo Alto, CA
 

Investor Relations Contact

John B. Thomas
SVP, Investor Relations & Corporate Communications
jthomas@assertiotx.com